Reuters logo
BRIEF-Merck says updated Keytruda findings show response rates benefit in head, neck cancer patients
2016年6月6日 / 中午12点22分 / 1 年前

BRIEF-Merck says updated Keytruda findings show response rates benefit in head, neck cancer patients

June 6 (Reuters) - Merck & Co Inc :

* Updated findings for Keytruda show continued benefit in response rates in patients with previously treated head and neck cancer

* Response rates from KEYNOTE-055 show nearly one in five patients responding with Keytruda; results confirm findings from KEYNOTE-012

* FDA granted priority review with a PDUFA, or action date, of August 9, 2016 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below